AU2011221553B2 - Monoclonal antibodies directed to CD20 - Google Patents

Monoclonal antibodies directed to CD20 Download PDF

Info

Publication number
AU2011221553B2
AU2011221553B2 AU2011221553A AU2011221553A AU2011221553B2 AU 2011221553 B2 AU2011221553 B2 AU 2011221553B2 AU 2011221553 A AU2011221553 A AU 2011221553A AU 2011221553 A AU2011221553 A AU 2011221553A AU 2011221553 B2 AU2011221553 B2 AU 2011221553B2
Authority
AU
Australia
Prior art keywords
antibody
antibodies
seq
canine
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011221553A
Other languages
English (en)
Other versions
AU2011221553A1 (en
Inventor
Genevieve Hansen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aratana Therapeutics Inc
Original Assignee
Vet Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vet Therapeutics Inc filed Critical Vet Therapeutics Inc
Publication of AU2011221553A1 publication Critical patent/AU2011221553A1/en
Application granted granted Critical
Publication of AU2011221553B2 publication Critical patent/AU2011221553B2/en
Priority to AU2016216710A priority Critical patent/AU2016216710A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2011221553A 2010-03-04 2011-03-04 Monoclonal antibodies directed to CD20 Ceased AU2011221553B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2016216710A AU2016216710A1 (en) 2010-03-04 2016-08-19 Monoclonal antibodies directed to cd20

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31044010P 2010-03-04 2010-03-04
US61/310,440 2010-03-04
PCT/US2011/000415 WO2011109108A1 (en) 2010-03-04 2011-03-04 Monoclonal antibodies directed to cd20

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2016216710A Division AU2016216710A1 (en) 2010-03-04 2016-08-19 Monoclonal antibodies directed to cd20

Publications (2)

Publication Number Publication Date
AU2011221553A1 AU2011221553A1 (en) 2012-10-25
AU2011221553B2 true AU2011221553B2 (en) 2016-05-26

Family

ID=44542488

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2011221553A Ceased AU2011221553B2 (en) 2010-03-04 2011-03-04 Monoclonal antibodies directed to CD20
AU2016216710A Abandoned AU2016216710A1 (en) 2010-03-04 2016-08-19 Monoclonal antibodies directed to cd20

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2016216710A Abandoned AU2016216710A1 (en) 2010-03-04 2016-08-19 Monoclonal antibodies directed to cd20

Country Status (6)

Country Link
EP (1) EP2542262A4 (https=)
JP (2) JP5911813B2 (https=)
AU (2) AU2011221553B2 (https=)
BR (1) BR112012022338A2 (https=)
CA (1) CA2791560A1 (https=)
WO (1) WO2011109108A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2411050A4 (en) 2009-03-25 2013-07-17 Vet Therapeutics Inc ANTIBODY REGIONS WITH A CONSTANT DOMAIN AND THEIR USE
EP2542258A4 (en) 2010-03-04 2013-08-21 Vet Therapeutics Inc ON CD52 MONOCLONAL ANTIBODIES
ES2704007T3 (es) * 2011-05-06 2019-03-13 Nexvet Australia Pty Ltd Anticuerpos anti-factor de crecimiento nervioso y procedimientos de preparación y uso de los mismos
AU2012328819B2 (en) * 2011-10-26 2017-08-03 Elanco Tiergesundheit Ag Monoclonal antibodies and methods of use
KR102131544B1 (ko) 2016-02-18 2020-07-07 엘랑코 유에스 인코포레이티드 키메라 개 항-cd20 항체
JP2019026625A (ja) * 2017-08-03 2019-02-21 日本全薬工業株式会社 抗イヌｃｄ２０モノクローナル抗体
JP2021059499A (ja) * 2019-10-03 2021-04-15 日本全薬工業株式会社 イヌｃｄ２０に対するモノクローナル抗体又は抗体フラグメント
EP4656205A1 (en) 2023-01-25 2025-12-03 Nippon Zenyaku Kogyo Co., Ltd. Method for treating canine b cell lymphoma

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030219433A1 (en) * 2002-02-14 2003-11-27 Immunomedics, Inc. Anti-CD20 antibodies and fusion proteins thereof and methods of use
US20040181039A1 (en) * 2001-12-21 2004-09-16 Krah Eugene Regis Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
US20050271662A1 (en) * 2004-05-28 2005-12-08 Idexx Laboratories, Inc. Canine CD20 compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JP3919830B2 (ja) * 1992-11-28 2007-05-30 財団法人化学及血清療法研究所 抗ネコヘルペスウイルス−１組換え抗体および該抗体をコードする遺伝子断片
JP3087696B2 (ja) 1997-07-25 2000-09-11 日本電気株式会社 分散メモリ型マルチプロセッサ・システム制御方法およびコンピュータ読み取り可能な記録媒体
EP1246607B1 (en) 1999-12-30 2007-06-27 Dana-Farber Cancer Institute, Inc. Proteoliposomes containing an integral membrane protein having one or more transmembrane domains
ZA200503075B (en) * 2002-11-07 2006-09-27 Immunogen Inc Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same
US20080299546A1 (en) * 2004-02-10 2008-12-04 Nihon University Canine Cd20 Gene
GB0707640D0 (en) 2007-04-20 2007-05-30 Strathclyde Acoustic deterrence
EP2331579B1 (en) 2008-09-04 2017-07-05 Vet Therapeutics, Inc. Monoclonal antibodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040181039A1 (en) * 2001-12-21 2004-09-16 Krah Eugene Regis Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
US20030219433A1 (en) * 2002-02-14 2003-11-27 Immunomedics, Inc. Anti-CD20 antibodies and fusion proteins thereof and methods of use
US20050271662A1 (en) * 2004-05-28 2005-12-08 Idexx Laboratories, Inc. Canine CD20 compositions

Also Published As

Publication number Publication date
AU2016216710A1 (en) 2016-09-08
JP2016179978A (ja) 2016-10-13
EP2542262A1 (en) 2013-01-09
CA2791560A1 (en) 2011-09-09
JP5911813B2 (ja) 2016-04-27
AU2011221553A1 (en) 2012-10-25
EP2542262A4 (en) 2014-02-26
BR112012022338A2 (pt) 2017-02-14
JP2013520990A (ja) 2013-06-10
WO2011109108A1 (en) 2011-09-09

Similar Documents

Publication Publication Date Title
US9616120B2 (en) Monoclonal antibodies directed to CD20
US8337842B2 (en) Monoclonal antibodies
AU2011223547B2 (en) Monoclonal antibodies directed to CD52
AU2011221553B2 (en) Monoclonal antibodies directed to CD20
JP2025076471A (ja) 抗ｓｔｅａｐ１抗原結合タンパク質
EP3743081A1 (en) Antibodies specific to delta 1 chain of t cell receptor
CN114728065A (zh) 针对cd3和bcma的抗体和自其制备的双特异性结合蛋白
JP2021522847A (ja) Ｏｘ４０に対する完全ヒト抗体、それを調製する方法、およびその使用
EP4292611A1 (en) Anti-cd112r antibody and use thereof
CN114981301B (zh) Pd1和vegfr2双结合剂
JP2026506565A (ja) 三重特異性抗原結合分子およびその使用
AU2014200771B2 (en) Monoclonal antibodies
AU2016216708A1 (en) Monoclonal antibodies
AU2009288700B2 (en) Monoclonal antibodies
RU2852663C1 (ru) Антитела против cd3 и bcma и биспецифичные связывающие белки, полученные из них
WO2022228545A1 (en) Antibodies and variants thereof against human 4-1bb
AU2016203429B2 (en) Binding Molecules to the Human OX40 Receptor
EA051475B1 (ru) Антитела к cd122 и их применение
HK40067877A (en) Antibodies to cd3 and bcma, and bispecific binding proteins made therefrom

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired